GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound I-85 [WO2020224652] | CT-1113
Compound class:
Synthetic organic
Comment: CT1113 is reported as an inhibitor of the deubiquitinating enzymes, ubiquitin specific peptidase 28 (USP28) and USP25 [2-3].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Peng J, Jiang K, Bu J, Wang F. (2020)
Ubiquitin-specific protease inhibitors, and preparation method therefor and application thereof. Patent number: WO2020224652A1. Assignee: Chaser Therapeutics Inc. Priority date: 08/05/2020. Publication date: 12/11/2020. |
2. Peng J, Jiang K, Sun X, Wu L, Wang J, Xi X, Tan X, Liang T, Tan C, Zhang P. (2022)
Identification of a class of potent USP25/28 inhibitors with broad-spectrum anti-cancer activity. Signal Transduct Target Ther, 7 (1): 393. [PMID:36481755] |
3. Xu J, Peng J, Sun S, Wang D, Yuan W, Yang X, Shi T, Wang R, Liu H, Zhang P et al.. (2024)
Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia. Br J Haematol, 204 (6): 2301-2318. [PMID:38685813] |